1
2
Drooger, J.C. (Jan), Tinteren, H. (Harm) van, de Groot, S.M. (Steffen M.), Tije, A.J. (Albert Jan) ten, Graaf, H. (Hiltje) de, Portielje, J.E.A. (Johanneke ), Jager, A. (Agnes), Honkoop, A.H. (Aafke H), Linn, S.C. (Sabine), Kroep, J.R. (Judith), Erdkamp, F.L.G. (Frans ), Hamberg, A.P. (Paul), Imholz, A.L.T. (Alex L. T.), van Rossum-Schornagel, Q.C. (Quirine C.), Heijns, J.B. (Joan), Leeuwen-Stok, A.E. van, Sleijfer, S. (Stefan)
2016
2016
3
Seferina, S.C., Lobbezoo, D.J.A., de Boer, M., Dercksen, M.W., van den Berkmortel, F., van Kampen, R.J.W., van de Wouw, A.J., de Vries, B., Joore, M.A., Peer, P.G.M., Voogd, A.C., Tjan-Heijnen, V.C.G.
Veröffentlicht in: Seferina , S C , Lobbezoo , D J A , de Boer , M , Dercksen , M W , van den Berkmortel , F , van Kampen , R J W , van de Wouw , A J , de Vries , B , Joore , M A , Peer , P G M , Voogd , A C & Tjan-Heijnen , V C G 2015 , ' Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium ' , Oncologist , vol. 20 , no. 8 , pp. 856-863 . https://doi.org/10.1634/theoncologist.2015-0006;
2015
Veröffentlicht in: Seferina , S C , Lobbezoo , D J A , de Boer , M , Dercksen , M W , van den Berkmortel , F , van Kampen , R J W , van de Wouw , A J , de Vries , B , Joore , M A , Peer , P G M , Voogd , A C & Tjan-Heijnen , V C G 2015 , ' Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium ' , Oncologist , vol. 20 , no. 8 , pp. 856-863 . https://doi.org/10.1634/theoncologist.2015-0006;
2015
4
5
6
Wagner, Anna Dorothea, Grabsch, Heike, Mauer, Murielle, Marreaud, Sandrine, Caballero, Carmela, Thuss-Patience, Peter, Mueller, Lothar, Elme, Annelie, Moehler, Markus Hermann, Martens, Uwe, Kang, Yoon-Koo, Rha, Sun Young, Cats, Annemieke, Tokunaga, Masanori, Lordick, Florian
Veröffentlicht in: Wagner , A D , Grabsch , H , Mauer , M , Marreaud , S , Caballero , C , Thuss-Patience , P , Mueller , L , Elme , A , Moehler , M H , Martens , U , Kang , Y-K , Rha , S Y , Cats , A , Tokunaga , M & Lordick , F 2019 , ' EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group ' , BMC Cancer , vol. 19 , 494 . https://doi.org/10.1186/s12885-019-5675-4;
2019
Veröffentlicht in: Wagner , A D , Grabsch , H , Mauer , M , Marreaud , S , Caballero , C , Thuss-Patience , P , Mueller , L , Elme , A , Moehler , M H , Martens , U , Kang , Y-K , Rha , S Y , Cats , A , Tokunaga , M & Lordick , F 2019 , ' EORTC-1203-GITCG - the "INNOVATION"-trial : Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group ' , BMC Cancer , vol. 19 , 494 . https://doi.org/10.1186/s12885-019-5675-4;
2019
7